Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Medtronic's INFUSE Bone Graft receives Prix Galien USA 2008 Award

Medtronic : 26 September, 2008  (Company News)
Medtronic's INFUSE Bone Graft, the company’s recombinant human bone morphogenetic protein technology, has received the Prix Galien USA 2008 Award for Best Biotechnology Product.
The Prix Galien USA Awards committee of 11, including seven Nobel Laureates, recognizes the technical, scientific and clinical research skills necessary to develop innovative medicines that improve the human condition, and is considered the industry's highest accolade for pharmaceutical research and development.

INFUSE Bone Graft is recombinant human Bone Morphogenetic Protein‑2 (rhBMP‑2) applied to an absorbable collagen sponge (ACS) carrier. The purpose of the protein, which occurs naturally in the body, is to stimulate bone formation. Researchers at Wyeth discovered the rhBMP‑2 protein. Medtronic’s research and development of rhBMP'2 combined with the ACS carrier, has led to the extensive clinical evaluations and the market introduction of INFUSE Bone Graft.

INFUSE Bone Graft has been approved by the FDA for use in certain lumbar spine fusion procedures with Medtronic titanium threaded interbody cages, tibial fracture repair procedures and also certain oral maxillofacial and dental regenerative bone grafting procedures. Implanted into a bone‑deficient site, INFUSE Bone Graft harnesses the power of the body to induce normal bone formation. INFUSE Bone Graft offers surgeons and their patients an alternative to autogenous bone grafting; eliminating the need to surgically harvest bone from other parts of the patient such as the shin, hip or chin.

“It is especially rewarding to have a product recognized for such a prestigious honour,” said Bill McKay, vice president of Biologics Research and Development at Medtronic. “This technology presents breakthrough biological therapeutic capabilities which have had a dramatic impact on patient care and is redefining the standard of care for bone regenerative surgery.”

Accepting the award on behalf of Wyeth and Medtronic, Mikael Dolsten, MD, PhD, president, Wyeth Research said, “Being selected to receive the Prix Galien USA award is truly an honour. This award reflects our commitment to developing innovative and much needed treatment options in bone repair.”
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo